CRISPR Therapeutics posted a Q2 net loss of $91.2 million, narrowing from $208.5 million a year earlier.
CASGEVY revenue rose to $76 million, up 78% from Q1 and more than doubled from a year earlier.
Cash, cash equivalents and marketable securities climbed to $2.36 billion at June 30 from $1.98 billion at Dec. 31, boosted by $585.4 million in convertible senior notes.
R&D expenses edged down to $67.2 million from $69.9 million, due to lower employee and facility costs, partly offset by higher license fees.
Pipeline and regulatory updates
The FDA expanded CASGEVY to children aged 2 and older.
Phase 1 trials began for CTX340 in refractory hypertension and CTX460 in alpha-1 antitrypsin deficiency.
CRSP•
